Prelude Therapeutics (PRLD)
Develops small-molecule oncology programs centered on JAK2V617F inhibition and KAT6A degradation.
Something off on this page? Send us feedback.
Develops precision-oncology drug candidates through a discovery engine spanning cancer biology, medicinal chemistry, and clinical development. Its pre-commercial pipeline centers on PRT12396, a mutant-selective JAK2V617F inhibitor, and PRT13722, an oral KAT6A degrader.
Develops precision-cancer medicines by combining cancer biology, medicinal chemistry, and clinical-development capabilities. The clinical-stage, pre-commercial pipeline centers on PRT12396, a mutant-selective JAK2V617F inhibitor in Phase 1 for polycythemia vera and myelofibrosis, alongside PRT13722, an oral KAT6A degrader at the IND stage.
The company also maintains precision degrader-antibody conjugate discovery. It operates as a single segment with no product sales, so its work depends on clinical progress, regulatory clearance, and financing. Prelude retains ownership and development responsibility for the JAK2 program while Incyte holds an option to acquire it during the option period.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Apr 27, 2026 | H.C. Wainwright | Target | Target: $5 | Target: $8 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $151.8M · Total debt $17.7M · Total assets $189.4M · Shareholders' equity $133.7M
- Revenue
- $5.7M
- Operating income
- −$15.5M
- Net income
- −$13.9M
No dividends on record.
| Institutions | 62.24% | 49.67M shares | |
|---|---|---|---|
| 83 holders · as of Jun 30, 2026 | |||
| Insiders | 1.05% | 837.0K shares | |
| 5 holders · as of Mar 19, 2026 | |||
| Other | 36.71% | 29.30M shares | |
| remainder | |||
79.80M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Orbimed Advisors LLCInstitution | 17.20% | 13.72M | as of Jun 30, 2026 |
Baker Bros. Advisors LPInstitution | 12.69% | 10.12M | as of Jun 30, 2026 |
Ra Capital Management, L.P.Institution | 8.11% | 6.48M | as of Jun 30, 2026 |
Soleus Capital Management, L.P.Institution | 4.23% | 3.38M | as of Jun 30, 2026 |
Kynam Capital Management, LPInstitution | 3.03% | 2.42M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Apr 21, 2026 | Orbimed Advisors LLC | director, 10 percent owner: | +2,815,315 | $4.44 |
| Apr 21, 2026 | David P. Bonita | director, 10 percent owner: | +2,815,315 | $4.44 |
| Apr 21, 2026 | Baker Bros. Advisors LP | director, 10 percent owner: | +2,252,252 | $0.0001 |
- Cogent Biosciences
Mutant-selective JAK2V617F program for the same MPN driver.
- Incyte
Marketed JAK1/JAK2 therapy for PV and myelofibrosis.
- Protagonist Therapeutics
Late-stage rusfertide program for polycythemia vera.
- Disc Medicine
Phase 2 anti-TMPRSS6 program for polycythemia vera.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Prelude Therapeutics | $4.38 | −9.69% | $276.1M | — | — | 12.3 | — |
| Cogent Biosciences | $31.02 | −4.92% | $5.58B | — | — | — | — |
| Incyte | $124.67 | −1.78% | $25.73B | 16.2 | 51.6 | 4.4 | +37.7% |
| Protagonist Therapeutics | $139.21 | −4.04% | $9.33B | 140.3 | 69.5 | 33.1 | +3,749.2% |
| Disc Medicine | $65.62 | −4.18% | $2.63B | — | — | — | — |
| Median | 78.3 | 60.6 | 18.8 | +1,893.4% |